Author

Charles Keller

Children's Cancer Therapy Development InstituteORCID 0000-0003-2505-7487Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Charles Keller1 paper · University of Houston - Downtown

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Atiya MansooriD· 1 shared Brian S. HernandeziD· 1 shared Carol J. BultiD· 1 shared Charity Conlin Jennings· 1 shared Elaine HuangiD· 1 shared Emma Lashyro· 1 shared Erin Wise· 1 shared Gillian St John· 1 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioinformatics

Atiya MansoorORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 21, 2026

Temporal Dynamics of SMARCA4 Loss Define Its Role in Myogenic Differentiation of Alveolar Rhabdomyosarcoma

Charity Conlin Jennings, Emma Lashyro, Jing Wang…·Charles Keller

This study shows that acute SMARCA4 loss in ARMS cells does not induce differentiation or alter proliferation, contrasting with long-term knockdown effects.

DOI 10.64898/2026.10.20.760536

mousebulk RNA-seq

𝕏 PostBluesky

BioinformaticsBMC CancerPeer-reviewedJun 17, 2019

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

Noah Berlow, Rishi Raj Rikhi, Mathew N. Geltzeiler…·Charles Keller

This paper develops a probabilistic model integrating sequencing and functional assay data to predict personalized drug combinations for sarcoma patients with exhausted treatment options.

21 citations

mousebulk RNA-seq

𝕏 PostBluesky